Reaction

Red Blood Cell Count Increased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,736 reports · 54 co-occurring drugs

As of the last recalculation, Red Blood Cell Count Increased appears in 2,736 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is DIMENHYDRINATE (PRR 31.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Dimenhydrinate	44	31.9	32.0
Alemtuzumab	71	28.6	28.7
Hydroxyurea	54	19.8	19.8
Ruxolitinib	146	16.3	16.3
Testosterone Cypionate	19	16.3	16.3
Ciclesonide	28	15.8	15.8
Testosterone	40	13.2	13.2
Clozapine	148	9.4	9.4
Niraparib	26	9.0	9.0
Rucaparib	9	7.8	7.8
Avapritinib	12	7.6	7.6
Lanreotide Acetate	7	6.8	6.8
Methimazole	7	6.8	6.8
Cetirizine Hcl	8	6.7	6.7
Moxifloxacin Hydrochloride	17	6.4	6.4
Ibrutinib	60	5.8	5.8
Omalizumab	63	5.7	5.7
Desoximetasone	14	5.6	5.6
Empagliflozin	47	5.4	5.4
Eltrombopag Olamine	15	5.0	5.0
Tiotropium Bromide Inhalation Spray	7	4.8	4.8
Modafinil	20	4.7	4.7
Nilotinib	18	4.7	4.7
Deferasirox	16	4.6	4.6
Selinexor	5	4.4	4.4
Ribociclib	18	4.4	4.4
Ocrelizumab	35	4.3	4.3
Axitinib	11	4.3	4.3
Paliperidone	12	3.9	3.9
Memantine	7	3.9	3.9
Memantine Hydrochloride	7	3.9	3.9
Fluticasone Furoate And Vilanterol Trifenatate	17	3.6	3.6
Asfotase Alfa	4	3.0	3.0
Somatropin	28	2.9	2.9
Olaparib	8	2.9	2.9
Peginterferon Beta-1A	5	2.9	2.9
Palbociclib	36	2.9	2.9
Fingolimod Hcl	32	2.8	2.8
Ravulizumab	5	2.8	2.8
Lenvatinib	12	2.8	2.8
Methoxy Polyethylene Glycol-Epoetin Beta	4	2.8	2.8
Dornase Alfa	7	2.7	2.7
Alpelisib	3	2.6	2.6
Diroximel Fumarate	4	2.6	2.6
Lurasidone Hydrochloride	7	2.5	2.5
Peginterferon Alfa-2A	17	2.4	2.4
Venetoclax	19	2.4	2.4
Ranitidine	59	2.3	2.3
Romosozumab-Aqqg	4	2.2	2.2
Cabozantinib	13	2.1	2.1
Pirfenidone	9	1.7	1.7
Dimethyl Fumarate	25	1.6	1.6
Voxelotor	4	1.4	1.4
Tirzepatide	24	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.